'1104

About Revolo Biotherapeutics

Revolo Biotherapeutics is a private, venture-funded biotechnology company pioneering an upstream, disease-agnostic approach to treating immune-mediated conditions. Its core technology involves peptide-based therapies that simultaneously upregulate regulatory T/B cells and downregulate effector T cells, aiming for rapid, prolonged effect without systemic immune suppression. The lead candidate '1104 has completed a Phase 2 trial in eosinophilic esophagitis (EoE), with plans for a larger Phase 2 trial in 2025, while '1805 is being prepared for Phase 2 trials in rheumatoid arthritis and ulcerative colitis. The company's strategy includes exploring convenient subcutaneous and sublingual administration routes to potentially disrupt the current treatment landscape.

About Revolo Biotherapeutics

Revolo Biotherapeutics is a private, venture-funded biotechnology company pioneering an upstream, disease-agnostic approach to treating immune-mediated conditions. Its core technology involves peptide-based therapies that simultaneously upregulate regulatory T/B cells and downregulate effector T cells, aiming for rapid, prolonged effect without systemic immune suppression. The lead candidate '1104 has completed a Phase 2 trial in eosinophilic esophagitis (EoE), with plans for a larger Phase 2 trial in 2025, while '1805 is being prepared for Phase 2 trials in rheumatoid arthritis and ulcerative colitis. The company's strategy includes exploring convenient subcutaneous and sublingual administration routes to potentially disrupt the current treatment landscape.

Therapeutic Areas

Other Eosinophilic Esophagitis (EoE) Drugs